On Feb. 4, 2021, Corvus Pharmaceuticals announced that it had initiated a Phase 3 clinical trial of CPI-006 for the treatment of hospitalized patients with COVID-19. The study was expected to enroll approximately 1,000 patients at sites in North America, Europe, South Africa and Latin America.